
Debiganto 150mg Tablet
Marketer
Shinto Organics (P) Limited
Salt Composition
Dabigatran Etexilate (150mg)
Overview Debiganto 150mg Tablet
Xylotol 150mg tablets function as an anticoagulant, preventing and treating blood clots. This medication mitigates stroke and heart attack risk by inhibiting clot formation in leg, lung, brain, and heart veins. Frequently prescribed for patients with atrial fibrillation to prevent clot formation, it also lowers clot risk post-knee or hip replacement. Administration is flexible—with or without food—but consistent daily timing is recommended. Long-term use, potentially lifelong, may be necessary; cessation or dosage alteration requires physician approval to avoid increased heart attack, stroke, or thrombosis risk. Lifestyle modifications, including smoking cessation, healthy eating, regular exercise, and weight management (if needed), further reduce clot risk. Common side effects include gastrointestinal discomfort and increased bleeding susceptibility (e.g., nosebleeds, bruising). Report any adverse effects promptly. Additional potential side effects encompass headaches, seizures, allergic responses, visual disturbances, and fatigue. Contraindications include severe hepatic or renal impairment, active bleeding, and concurrent use of other anticoagulants. Breastfeeding is not advised during treatment. Unlike some anticoagulants, routine PT-INR monitoring is unnecessary.
Primary Ingredients of Debiganto 150mg Tablet
No text provided. Please provide the text you want me to rephrase.
Uses of Debiganto 150mg Tablet
Preventing and managing blood clots
Major Benefits of Debiganto 150mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Debiganto 150mg Tablets can be consumed with or without food, although consistent timing is recommended.
Common Side effects of Debiganto 150mg Tablet:
- Nausea
- Anemia (low number of red blood cells)
- Gastrointestinal bleeding
- Dyspepsia
- Diarrhea
- Abdominal pain
- Nosebleeds
- Skin bleeding
How to use Debiganto 150mg Tablet:
Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the 150mg Debiganto tablet whole; avoid chewing, crushing, or fracturing it. Consumption may coincide with meals or be taken independently, although consistent timing is recommended.
How Debiganto 150mg Tablet works:
Xyloban 150mg tablets are a new oral anticoagulant, inhibiting blood clot development.
SAFETY ADVICE
AlcoholUNSAFE
Combining Debiganto 150mg Tablet and alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
Use of Debiganto 150mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the unborn child. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Lactation and Debiganto 150mg tablets are likely incompatible. Available human data indicates a potential for the medication to transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Debiganto 150mg Tablets.
KidneyCAUTION
Individuals with severe kidney impairment should exercise caution when using Debiganto 150mg tablets, as dose modification may be necessary. Consultation with a physician is advised. Debiganto 150mg tablets are generally unsuitable for patients suffering from severe kidney disease.
LiverCAUTION
Patients with liver impairment should use Debiganto 150mg tablets cautiously, potentially requiring dosage modification. A physician's consultation is advised.
What if you forget to take Debiganto 150mg Tablet :
Should you forget a Debiganto 150mg Tablet dose, administer it immediately upon recollection that same day. However, omit the missed dose if it's less than six hours until your next scheduled intake. Never compensate for a missed dose by taking two tablets at once.
Facts to Know About Debiganto 150mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Benzimidazole-based compound |
| Developing Habits | No. |
| Type of Therapy | Heart |
| Behavior Class | Oral direct thrombin inhibitor |
